Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
UPenn Expert Discussion on Lymphoma: Efficacy of Acalabrutinib for Severe COVID-19, Time-Limited Venetoclax / Obinutuzumab, Brentuximab Mono in HL
Comments 0
Login to view comments.
Click here to Login